Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruno Fautrel

Showing results (221-230 of 371) with videos related to

Pageof 38
Sort By:
RMD Open|January 8, 2026
Effects of upadacitinib or adalimumab on pain in rheumatoid arthritis and psoriatic arthritis: results from randomised phase 3 studiesPeter C Taylor, Arthur Kavanaugh, Louis Bessette, et al.
Arthritis and Rheumatism|July 9, 2003
Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacyJacques-Eric Gottenberg, Florence Merle-Vincent, Fabrice Bentaberry, et al.
Drugs - Real World Outcomes|January 17, 2025
Correction: Real-World Evidence of Clinical Outcomes of the Use of the Adalimumab Biosimilar SB5 in Rheumatic and Gastrointestinal Immune-Mediated Inflammatory Diseases: 12-Month Data from the PERFUSE StudyBruno Fautrel, Yoram Bouhnik, Carine Salliot, et al.
Drugs - Real World Outcomes|October 9, 2024
Real-World Evidence of Clinical Outcomes of the Use of the Adalimumab Biosimilar SB5 in Rheumatic and Gastrointestinal Immune-Mediated Inflammatory Diseases: 12-Month Data from the PERFUSE StudyBruno Fautrel, Yoram Bouhnik, Carine Salliot, et al.
Rheumatology International|April 10, 2024
Disease activity and widespread pain are main contributors to patient-reported global health in axial spondyloarthritis: an analysis of 6064 patientsJuliette Drouet, Clementina López-Medina, Benjamin Granger, et al.
Rheumatology (Oxford, England)|November 17, 2011
Assessment of work instability in spondyloarthritis: a cross-sectional study using the ankylosing spondylitis work instability scaleIsabelle Fabreguet, Eugénie Koumakis, Vincent Burki, et al.
Health and Quality of Life Outcomes|July 8, 2015
Relationship between optimism and quality of life in patients with two chronic rheumatic diseases: axial spondyloarthritis and chronic low back pain: a cross sectional study of 288 patientsSarah Kreis, Anna Molto, Florian Bailly, et al.
Joint Bone Spine|November 6, 2021
Fluctuation of pain is frequent in rheumatoid arthritis and axial spondyloarthritis: A 12 weeks prospective study of 165 patientsJuliette Drouet, Laure Gossec, Charlotte Jacquemin, et al.
Rheumatology (Oxford, England)|August 3, 2022
JAK inhibitors in difficult-to-treat adult-onset Still's disease and systemic-onset juvenile idiopathic arthritisLouise Gillard, Jacques Pouchot, Fleur Cohen-Aubart, et al.
Journal of Crohn'S & Colitis|May 8, 2026
Safety of advanced therapies during pregnancy in women with immune-mediated inflammatory diseases: a systematic review and meta-analysisOphelie Pingeon, Nathan Grellier, Bénédicte Coulm, et al.
Pageof 38

Showing results (221-230 of 371) with videos related to

Sort By:
Pageof 38
RMD Open|January 8, 2026
Effects of upadacitinib or adalimumab on pain in rheumatoid arthritis and psoriatic arthritis: results from randomised phase 3 studiesPeter C Taylor, Arthur Kavanaugh, Louis Bessette, et al.
Arthritis and Rheumatism|July 9, 2003
Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacyJacques-Eric Gottenberg, Florence Merle-Vincent, Fabrice Bentaberry, et al.
Drugs - Real World Outcomes|January 17, 2025
Correction: Real-World Evidence of Clinical Outcomes of the Use of the Adalimumab Biosimilar SB5 in Rheumatic and Gastrointestinal Immune-Mediated Inflammatory Diseases: 12-Month Data from the PERFUSE StudyBruno Fautrel, Yoram Bouhnik, Carine Salliot, et al.
Drugs - Real World Outcomes|October 9, 2024
Real-World Evidence of Clinical Outcomes of the Use of the Adalimumab Biosimilar SB5 in Rheumatic and Gastrointestinal Immune-Mediated Inflammatory Diseases: 12-Month Data from the PERFUSE StudyBruno Fautrel, Yoram Bouhnik, Carine Salliot, et al.
Rheumatology International|April 10, 2024
Disease activity and widespread pain are main contributors to patient-reported global health in axial spondyloarthritis: an analysis of 6064 patientsJuliette Drouet, Clementina López-Medina, Benjamin Granger, et al.
Rheumatology (Oxford, England)|November 17, 2011
Assessment of work instability in spondyloarthritis: a cross-sectional study using the ankylosing spondylitis work instability scaleIsabelle Fabreguet, Eugénie Koumakis, Vincent Burki, et al.
Health and Quality of Life Outcomes|July 8, 2015
Relationship between optimism and quality of life in patients with two chronic rheumatic diseases: axial spondyloarthritis and chronic low back pain: a cross sectional study of 288 patientsSarah Kreis, Anna Molto, Florian Bailly, et al.
Joint Bone Spine|November 6, 2021
Fluctuation of pain is frequent in rheumatoid arthritis and axial spondyloarthritis: A 12 weeks prospective study of 165 patientsJuliette Drouet, Laure Gossec, Charlotte Jacquemin, et al.
Rheumatology (Oxford, England)|August 3, 2022
JAK inhibitors in difficult-to-treat adult-onset Still's disease and systemic-onset juvenile idiopathic arthritisLouise Gillard, Jacques Pouchot, Fleur Cohen-Aubart, et al.
Journal of Crohn'S & Colitis|May 8, 2026
Safety of advanced therapies during pregnancy in women with immune-mediated inflammatory diseases: a systematic review and meta-analysisOphelie Pingeon, Nathan Grellier, Bénédicte Coulm, et al.
Pageof 38